Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
NEW YORK - Tang Capital Management, LLC disclosed on April 25, 2025, that it has acquired a position in Mural Oncology Plc, representing 0.9% of the company’s shares. This announcement comes as part of the regulatory requirements under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022, which mandates disclosure by individuals or entities holding interests in relevant securities of 1% or more.
The position held by Tang Capital includes 152,159 shares of Mural Oncology, and was last updated on April 24, 2025, the day before the disclosure. Additionally, the firm engaged in the sale of 60,092 Mural Oncology shares at a price of $2.69 per share.
Tang Capital Management, through its general partner, also represents Tang Capital Partners (WA:CPAP), LP and Tang Capital Partners International, LP in these holdings. The disclosure did not report any cash-settled or stock-settled derivative positions, nor any other forms of dealing arrangements such as indemnity or option arrangements related to Mural Oncology’s shares.
The filing also confirmed that there are no agreements, arrangements, or understandings relating to the voting rights of any relevant securities under any options, or pertaining to the voting rights or future acquisition or disposal of any relevant securities to which any derivatives might be referenced.
This disclosure is part of standard procedure for investment firms and does not necessarily indicate a strategic change or intent regarding Tang Capital Management’s investment in Mural Oncology. The information provided is based on a press release statement, and further details or implications of the disclosed position are not available at this time.
Investors and market watchers often monitor such disclosures to gauge investment trends and sentiment, particularly in the context of potential takeovers or significant changes in company ownership. Mural Oncology, along with other market participants, will continue to be subject to such disclosures as part of regulatory compliance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.